CARB-X 2021-22 ANNUAL REPORT LAUNCHED
CARB-X published its 2021-2022 annual report today. The report highlights achievements, including CARB-X projects in clinical development, new products on the market, renewed funding commitments, open funding rounds, and Portfolio Acceleration Tools, a series of research projects led by CARB-X to support multiple product developers.
Over the past year, CARB-X product developers made tremendous progress advancing their projects through the development pipeline:
- 8 prevention and therapeutic candidates began or progressed through Phase 1 and Phase 1b clinical trials. These represent a range of modalities, including broad-spectrum antibiotics by Bugworks and Peptilogics, biofilm-targeting monoclonal antibodies by Trellis Bioscience and Clarametyx Biosciences, a CRISPR-engineered bacteriophage by SNIPR Biome, a live biotherapeutic candidate by Seres Therapeutics, and both a vaccine and a small-molecule anti-virulence inhibitor by GlaxoSmithKline;
- Vedanta Biosciences entered Phase 3 clinical trials with a live biotherapeutic candidate;
- 2 diagnostics by HelixBind and Proteus entered the verification and validation stage; and
- 2 diagnostics by T2 Biosystems and Specific Diagnostics (acquired by bioMérieux in 2022) are now on the market.
Join the AMR Insights Ambassador Network today!
Connect to over 650 AMR professionals and students in 65 countries!